Professor and Chairman of Surgery
Urology
Robert Uzzo is an expert in the field of Urology. He went to Weill Cornell Medical College of Cornell University. Weill Cornell Medical College of Cornell University is ranked 18 in research and 49 in primary care medicine He over the years received 38 awards: "America's Top Doctors", "Philadelphia Magazine", "Ranked first in Philadelphia and top 10% among Comprehensive Cancer Centers Nationally", "CMS Meaningful Use Stage 1 Certification", "America's Top Doctors for Cancer", "Fox Chase Presidential Inspired Leadership Award", "Winner, Best Poster in Session", "Co-leader, Kidney Cancer Keystone Program", "AUA Honorable Mention", "Winner, Honorable Mention, Best Videos at Meeting", "Winner, Resident Essay Contest", "Young Investigators Award", "Americas Top Physicians", "Americas Top Doctors for Cancer", "Winner, Best Poster", "Voted one of Top Doctors in Philadelphia", "Clinical Science Award", "The Pfizer Physician Scholar in Urology Award", "Young Investigator Award", "Circon Award First Place", "The Lower Award First Prize", "Austrian/American Foundation Fellowship", "The American Foundation for Urologic Diseases Scholar", "Circon Award Honorable Mention", "First Prize", "Third Prize", "The Coats Memorial Scholarship", "New York State Finalist", "Valedictorian", "Phi Beta Kappa - Alpha Chapter of New York", "The Terril Graduate Fellowship", "The National Italian American Foundation Scholarship", "The Dana Foundation Grant", "The Golub Fellowship", "The Dante Scholarship", "Math, Science, History, English Awards", "Top MD" and "Super Doctor". Robert Uzzo is a published MD as well. He has 58 publications published. The latest was: Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Robert Uzzo is registered with Medicare and accepts Medicare payments.
Publications
- The role of radical prostatectomy in high-risk localized, node-positive and metastatic prostate Cancer.
- Adjuvant sunitinib or sorafenib for high-risk, non-metastatic Renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.
- Advanced small cell carcinoma of the Bladder: clinical characteristics, treatment patterns and outcomes in 960 patients and comparison with urothelial carcinoma.
- Fox Chase Cancer Center's Genitourinary Division: a national resource for research, innovation and patient care.
- Effectiveness of androgen-deprivation therapy and radiotherapy for older men with locally advanced prostate Cancer.
- Variation in performance of candidate surgical quality measures for muscle-invasive bladder Cancer by hospital type.
- The burden of overtreatment: comparison of toxicity between single and combined modality radiation therapy among low risk prostate Cancer patients.
- A Simple Method for Evaluating Within-Sample Prognostic Balance Achieved by Published Comorbidity Summary Measures.
- Reply to Vincenzo Ficarra, Vito Palumbo, Afrovita Kungulli, and Gianluca Giannarini's Letter to the Editor re: Andrea Minervini, Marco Carini, Robert G. Uzzo, Riccardo...
- Care Transitions between Hospitals are Associated with Treatment Delay for Patients with Muscle Invasive Bladder Cancer.
- Evaluating toxicity from definitive radiation therapy for prostate Cancer in men with inflammatory bowel disease: Patient selection and dosimetric parameters with mode...
- Heterogeneity and Renal mass biopsy: a review of its role and reliability.
- Coupling of Prostate and Thyroid Cancer Diagnoses in the United States.
- Focal Therapy for Treatment of the Small Renal Mass: Dealer's Choice or a Therapeutic Gamble?
- Standardized Reporting of Resection Technique During Nephron-sparing Surgery: The Surface-Intermediate-Base Margin Score.
- Low rates of adjuvant radiation in patients with nonmetastatic prostate Cancer with high-risk pathologic features.
- Increasing use of dose-escalated external beam radiation therapy for men with nonmetastatic prostate Cancer.
- PD-1 Expression on Peripheral Blood Cells Increases with Stage in Renal Cell Carcinoma Patients and Is Rapidly Reduced after Surgical Tumor Resection.
- Thinking beyond surgery in the management of Renal cell carcinoma: the risk to die from Renal cell carcinoma and competing risks of death.
- The rise and fall of prostate brachytherapy: Use of brachytherapy for the treatment of localized prostate Cancer in the National Cancer Data Base.
- Growth Kinetics and Short Term Outcomes of cT1b and cT2 Renal Masses Under Active Surveillance.
- Is radical nephrectomy a legitimate therapeutic option in patients with Renal masses amenable to nephron-sparing surgery?
- Piperlongumine promotes autophagy via inhibition of Akt/mTOR signalling and mediates Cancer cell death.
- A global profile of gene promoter methylation in treatment-naïve urothelial Cancer.
- Coexisting hybrid malignancy in a solitary sporadic solid benign Renal mass: implications for treating patients following Renal biopsy.
- MicroRNA expression signatures of stage, grade, and progression in clear cell RCC.
- Trends in regionalization of radical cystectomy in three large northeastern states from 1996 to 2009.
- Randomized trial of hypofractionated external-beam radiotherapy for prostate Cancer.
- Association of tumor size with metastatic potential and survival in patients with adrenocortical carcinoma: an analysis of the National Cancer Database.
- Adjuvant and neoadjuvant therapy for Renal cell carcinoma: A survey of the Society of Urologic Oncology.
- Thermal ablation of the small Renal mass: Case selection using the R.E.N.A.L.-Nephrometry Score.
- Renal Pelvic Anatomy Is Associated with Incidence, Grade, and Need for Intervention for Urine Leak Following Partial Nephrectomy.
- Familiarity and Self-Reported Compliance with American Urological Association Best Practice Recommendations for Use of Thromboembolic Prophylaxis among American Urolog...
- Multi-institutional validation of the ability of preoperative Hydronephrosis to predict advanced pathologic tumor stage in upper-tract urothelial carcinoma.
- Use of radical cystectomy as initial therapy for the treatment of high-grade T1 urothelial carcinoma of the Bladder: A SEER database analysis.
- Gleason Scoring at a Comprehensive Cancer Center: What's The Difference?
- Nephron Sparing Management versus Radical Nephroureterectomy for Low or Moderate Grade, Low Stage Upper Tract Urothelial Carcinoma.
- Comparison of prostate Cancer diagnosis in patients receiving unrelated urological and non-urological Cancer care.
- Differential use of partial nephrectomy for intermediate and high complexity Tumors may explain variability in reported utilization rates.
- Balancing Process and Risk: Standardizing Posttreatment Surveillance for Renal Cell Carcinoma.
- A review of contemporary data on surgically resected Renal masses--benign or malignant?
- The Kubler-Ross model, physician distress, and performance reporting.
- Active surveillance of small Renal masses.
- Zinc and zinc transporters in Prostate carcinogenesis.
- Lymphopenia is an Independent Predictor of Inferior Outcome in Clear Cell Renal Carcinoma.
- Clinical characteristics associated with treatment type for localized Renal tumors: implications for practice pattern assessment.
- Partial Versus Radical Nephrectomy: Balancing Nephrons and Perioperative Risk.
- Pathological concordance and surgical outcomes of sporadic synchronous unilateral multifocal Renal masses treated with partial nephrectomy.
- Positron emission tomography/computed tomography identification of clear cell Renal cell carcinoma: results from the REDECT trial.
- Piperlongumine induces rapid depletion of the androgen receptor in human prostate Cancer cells.
- Competing risks of death in patients with localized Renal cell carcinoma: a comorbidity based model.
- The effect of 5-aminolevulinic acid and its derivatives on protoporphyrin IX accumulation and apoptotic cell death in castrate-resistant prostate Cancer cells.
- Does partial nephrectomy result in a durable overall survival benefit in the Medicare population?
- Age, tumor size and relative survival of patients with localized Renal cell carcinoma: a surveillance, epidemiology and end results analysis.
- Histopathological characteristics of localized Renal cell carcinoma correlate with tumor size: a SEER analysis.
- Cryoablation or radiofrequency ablation of the small Renal mass : a meta-analysis.
- Genome-wide promoter methylome of small Renal masses.
Schools
Joan Sanford I Weill Medical College Of Cornell University
New York HospitalCornell University Medical Center
The Cleveland Clinic Foundation Institute Of Urology
Procedures Preformed
- AdRenalectomy
- AdRenalectomy With Robotic Assistance
- Complete Nephrectomy With Robotic Assistance
- Cystectomy
- View All
Conditions Treated
- AdRenal Gland Cancer
- AdRenal Gland Diseases
- Bladder Cancer
- Bladder Infection
- View All
Doctors Specialties
Accepted Insurances
Awards
- America's Top Doctors
- Philadelphia Magazine
- Ranked first in Philadelphia and top 10% among Comprehensive Cancer Centers Nationally
- CMS Meaningful Use Stage 1 Certification
- America's Top Doctors for Cancer
- Fox Chase Presidential Inspired Leadership Award
- Winner, Best Poster in Session
- Co-leader, Kidney Cancer Keystone Program
- AUA Honorable Mention
- Winner, Honorable Mention, Best Videos at Meeting
- Winner, Resident Essay Contest
- Young Investigator’s Award
- America’s Top Physicians
- America’s Top Doctors for Cancer
- Winner, Best Poster
- Voted one of “Top Doctors†in Philadelphia
- Clinical Science Award
- The Pfizer Physician Scholar in Urology Award
- Young Investigator Award
- Circon Award – First Place
- The Lower Award – First Prize
- Austrian/American Foundation Fellowship
- The American Foundation for Urologic Diseases Scholar
- Circon Award – Honorable Mention
- First Prize
- Third Prize
- The Coats Memorial Scholarship
- New York State Finalist
- Valedictorian
- Phi Beta Kappa - Alpha Chapter of New York
- The Terril Graduate Fellowship
- The National Italian American Foundation Scholarship
- The Dana Foundation Grant
- The Golub Fellowship
- The Dante Scholarship
- Math, Science, History, English Awards
- Top MD
- Super Doctor
Education
-
Cleveland Clinic Foundation
-
New York Presbyterian Hospital - Cornell Campus
-
Memorial Sloan-Kettering Cancer Center
-
Weill Cornell Medical College of Cornell University
Hospital
-
Abington Hospital - Jefferson Health
-
Fox Chase Cancer Center-American Oncologic Hospital
-
Temple University Hospital
Drug Facts
| NPI NUMBER |
|
1841247194 |
| NPPES Provider LastName |
|
UZZO |
| NPPES Provider FirstName |
|
ROBERT |
| NPPES Provider ZIPCode |
|
190013800 |
| NPPES Provider State |
|
PA |
| Specialty Description |
|
Urology |
| Total Claim Count |
|
254.0 |
| Distinct Opioid Count |
|
0.0 |
| Opioid Claim Count |
|
0.0 |
| Percent Opioid Claims |
|
0.0 |
Helpful Reviews
Give
Anonymous Review
Medicare Facts
| National Provider Identifier [NPI] |
1841247194 |
| Last Name Of The Provider |
UZZO |
| First Name Of The Provider |
ROBERT |
| View All |
|
Similar Doctors
Doctor Directory | TOS | twitter | FB | Angel | blog
This Doctor is OpenDoctor Recommended.
This doctor has more publications